Research Paper Volume 13, Issue 23 pp 25466—25483

Prognostic value of CDCA3 in kidney renal papillary cell carcinoma

Hao Li1, , Mi Li1, , Caihong Yang1, , Fengjing Guo1, , Sisi Deng3, , Lixi Li2, , Tian Ma1, , Jiyuan Yan1, , Hua Wu1, , Xiaojuan Li2, ,

  • 1 Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
  • 2 Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
  • 3 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China

Received: October 9, 2020       Accepted: November 22, 2021       Published: December 14, 2021
How to Cite

Copyright: © 2021 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Kidney renal papillary cell carcinoma (KIRP) is a type of low-grade malignant renal cell carcinoma. Huge challenges remain in the treatment of KIRP. Cell division cycle associated 3 (CDCA3) participates in human physiological and pathological processes. However, its role in KIRP has not been established. Here, we evaluated the prognostic value of CDCA3 in KIRP using a comprehensive bioinformatics approach. Data for CDCA3 expression in KIRP were obtained from online database. Different expression genes between high and low CDCA3 expression groups were identified and evaluated by performing Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. A gene set enrichment analysis was performed to elucidate the function and pathway differences between the different. Differences in immune cell infiltration between low and high CDCA3 expression groups were analyzed by a single-sample GSEA method for immune cells. A protein-protein interaction network was generated and hub genes were identified. UALCAN was used to analyze associations between the mRNA expression levels of CDCA3 in KIRP tissues with clinicopathologic parameters. The diagnostic efficacy of CDCA3 for KIRP was analyzed by ROC analysis. Logistic regression was used to analyze relationships between the clinicopathological characteristics and CDCA3 expression. Our results indicated that high CDCA3 mRNA expression is significantly associated with some clinicopathologic parameters in KIRP patients High CDCA3 mRNA expression associated with a shorter overall survival, progression-free interval, and disease-special survival. Taken together, CDCA3 is a potential target for the development of anti-KIRP therapeutics and is an efficient prognostic marker.


RCC: Renal cell carcinoma; KIRP: Kidney renal papillary cell carcinoma, also known as papillary renal cell carcinoma (PRCC); CT: computed tomography; MRI: computed tomography; CDCA3: Cell division cycle associated 3; TCGA: The Cancer Genome Atlas; GO: Gene Ontology; DEGs: differential expression genes; GSEA: gene set enrichment analysis; PPI: protein-protein interaction; FPKM: fragments per kilobase per million; TPM: transcripts per million reads; KEGG: Kyoto Encyclopedia of Genes and Genomes; DCs: dendritic cells (DCs); aDCs: activated DCs (aDCs); pDCs: plasmacytoid DCs; iDCs: immature DCs; Th: T helper cells (Th); Treg: Regulatory T cells (Treg); Tgd: T gamma delta; Tcm: T central memory; Tem: T effector memory; Tfh: T follicular helper; MCODE: Molecular Complex Detection); ROC: Receiver Operating Characteristic; AUC: area under the curve; FPR: False Positive Rate; TPR: True Positive Rate; OS: overall survival; PFI: progression-free interval; DSS: disease-specific survival.